- Biotech company Next Science (NXS) has received CE Mark approval for its BlastX product
- This approval allows Next Science to apply and sell BlastX in each market in the European Union and the United Kingdom
- BlastX is an antimicrobial wound gel that deconstructs the bacterial biofilm and eliminates the bacteria in wounds to maintain a moist wound environment favourable for healing
- It is used for the treatment of non-healing wounds such as venous leg ulcers, diabetic foot ulcers, and bed sores
- Next Science has ended the day 9.7 per cent in the green with shares trading at $1.30
Next Science (NXS) has received CE Mark approval for its BlastX product.
This approval allows Next Science to apply and sell BlastX in each market in the European Union and the United Kingdom.
Additionally, this approval is the second for the company, having received CE Mark approval for its Bactisure Surgical Lavage Product in March.
BlastX is an antimicrobial wound gel that deconstructs the bacterial biofilm and eliminates the bacteria in wounds to maintain a moist wound environment favourable for healing.
It is used for the treatment of non-healing wounds such as venous leg ulcers, diabetic foot ulcers, and bed sores. It also prevents infections in acute wounds and surgical wounds.
Wounds such as these are difficult to treat, cause a decline in quality of life, and increase mortality, pain, and suffering.
A study completed in Texas showed that combining BlastX with custom antibiotics increased chronic wound closures by 40 per cent in a four-week randomised controlled trial.
“The receipt of a CE Mark approval for BlastX represents the successful conclusion of three years of work and marks a major milestone for Next Science as we pursue our mission to heal patients and save lives worldwide by reducing the impacts of biofilms on human health,” Managing Director Judith Mitchell said.
“The CE Mark is a minimum requirement for many other jurisdictions so we can now work on further approvals,” she added.
Next Science has ended the day 9.7 per cent in the green, with shares trading at $1.30 in a $230.1 million market cap.